Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDX104 for Prevention of EGFRI Skin Toxicity
NCT02239731Phase 2Completed
- Sponsor
- Vyne Therapeutics
- Start
- Oct 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of FDX104 in acneiform eruption, sponsored by Vyne Therapeutics. Started Oct 2014; status: completed.
02
Drugs
FDX104
03
Conditions
acneiform eruption
Beyond the preview
Go deeper on NCT02239731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02239731.